ProCE Banner Activity

Results of a Pooled Outcomes Analysis of Phase III Trials Using a Second Course of Pembrolizumab in Advanced NSCLC

Slideset Download
Results from a pooled outcomes analysis of 5 phase III trials suggest benefit of a second course of pembrolizumab in patients with advanced or metastatic NSCLC who had previously completed 35 cycles of therapy with pembrolizumab ± chemotherapy.

Released: August 16, 2022

Expiration: August 15, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc